Drawing based on the label description. No photo yet.
“Yellow, oval shaped, biconvex, bevelled edge film coated tablet, debossed with "TC 3" one side and plain on other side”
TC3 pill
Pill with imprint TC3 is yellow, oval, 15 mm and has been identified as Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide 40 mg / 5 mg / 25 mg. It is used for high blood pressure. It is supplied by Slate Run Pharmaceuticals, LLC.
Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide 40 mg / 5 mg / 25 mg
- Imprint
- TC3
- Strength
- Olmesartan Medoxomil 40 mg / Amlodipine 5 mg / Hydrochlorothiazide 25 mg
- Used for
- High blood pressure
- Color
- Yellow
- Shape
- Oval
- Size
- 15 mm
- Score
- No score line
- Form
- Tablet, film coated
- Manufacturer
- Slate Run Pharmaceuticals, LLC
- Drug class
- ARB (blood pressure medicine)
- NDC
- 70436-016, 70436-016-04, 70436-016-06
Source: the official drug label on DailyMed (US National Library of Medicine). Last checked .
Report a mistake
All Olmesartan Medoxomil and Amlodipine and Hydrochlorothiazide pills and guides
What is Olmesartan Medoxomil and Amlodipine and Hydrochlorothiazide used for?
Olmesartan Medoxomil and Amlodipine and Hydrochlorothiazide is used for high blood pressure.
- Medicine type
- ARB (blood pressure medicine); calcium channel blocker (blood pressure and heart medicine)
Official uses from the US prescribing label
Olmesartan medoxomil, amlodipine, hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine, and hydrochlorothiazide tablets.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy.
Limitations of Use
This fixed combination drug is not indicated for the initial therapy of hypertension.
From the FDA-approved label on DailyMed (published Jun 05, 2025).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your pill? Check every detail
- One side shows TC 3 and the other side is plain.
- It is yellow, oval, 15 mm.
- Its score line and coating match the details on this page.
- It came from a pharmacy package that names the same drug.
Ingredients
Active: Olmesartan Medoxomil, Amlodipine Besylate, Hydrochlorothiazide
Inactive: Croscarmellose Sodium, Ferric Oxide Yellow, Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, Peg-10 .beta.-Sitosteryl Ether, Polyvinyl Alcohol (100000 Mw), Silicon Dioxide, Starch, Corn, Talc, Titanium Dioxide
Pills that look similar but are different drugs
Same color and shape, different medicine. This is why the imprint matters.
-
SAV 002
Sacubitril and Valsartan 49 mg / 51 mg
Yellow, oval, 15 mm
Used for heart failure
-
G 4
Oxcarbazepine 300 mg
Yellow, oval, 15 mm
Used for focal seizures
-
93 7368
Losartan Potassium and Hydrochlorothiazide 100 mg / 25 mg
Yellow, oval, 15 mm
Used for high blood pressure and quitting smoking
- Lilly 150 Abemaciclib 150 mg Yellow, oval, 14 mm Used for breast cancer
- A002 Olmesartan Medoxomil and Hydrochlorothiazide 40 mg / 12.5 mg Yellow, oval, 15 mm Used for high blood pressure
- OX150 APO Oxcarbazepine 150 mg Yellow, oval, 16 mm Used for focal seizures
Other Olmesartan Medoxomil and Amlodipine and Hydrochlorothiazide pills
- C51 Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide 20 mg / 5 mg / 12.5 mg Orange, round, 8 mm Used for high blood pressure
- TEVA 5005 Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 20 mg / 5 mg / 12.5 mg Pink, round, 8 mm Used for high blood pressure
- TC1 Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide 20 mg / 5 mg / 12.5 mg Orange, round, 8 mm Used for high blood pressure
- T21 Olmesartan Medoxomil Amlodipine and Hydrochlorothiazide 20 mg / 5 mg / 12.5 mg Orange, round, 8 mm Used for high blood pressure
- H O12 Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 20 mg / 5 mg / 12.5 mg Orange, round, 8 mm Used for high blood pressure
- 85 I Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide 20 mg / 5 mg / 12.5 mg Orange, round, 8 mm Used for high blood pressure
- TEVA 5003 Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide 40 mg / 10 mg / 12.5 mg Pink, round, 10 mm Used for high blood pressure
- TC4 Olmesartan Medoxomil and Amlodipine Besylate and Hydrochlorothiazide 40 mg / 10 mg / 12.5 mg Pink, round, 10 mm Used for high blood pressure